penpulimab
Penpulimab-kcqx is a PD-1 checkpoint inhibitor from Akeso Biopharma for non-keratinizing nasopharyngeal carcinoma. It is used with platinum chemotherapy plus gemcitabine as first-line treatment of recurrent or metastatic disease, and alone after platinum-based chemotherapy and at least one later line of therapy.
This page is based on FDA prescribing information for penpulimab-kcqx, cross-checked with DailyMed and the National Cancer Institute dictionary; the mechanism is explained in plain language, and analogies are used only where they stay accurate.
How it works
Explains what the medicine does in the body, not dosing, side effects, or safety.
An analogy
Tumours in the nasopharynx can raise a molecular white flag that presses the PD-1 brake on attacking T cells, so the immune patrol stands down. Penpulimab covers the brake. The flag no longer works, the T cells stay switched on, and they attack the cancer alongside chemotherapy or on their own in later lines of treatment.
In simple terms
Penpulimab is a monoclonal antibody given by intravenous infusion that targets PD-1, an off-switch expressed on T cells. Many cancers display the ligands PD-L1 and PD-L2, which bind PD-1 and suppress the immune response against them. Penpulimab binds PD-1 and blocks that signalling, restoring T-cell activation and T-cell-mediated attack on tumour cells. It is used for non-keratinizing nasopharyngeal carcinoma, with platinum chemotherapy and gemcitabine in the first-line setting and as a single agent after the disease has progressed through platinum-based chemotherapy and at least one other line of therapy.
In depth
Penpulimab is a monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1, PDCD1, CD279). Upon administration it targets, binds to, and inhibits PD-1 and its downstream signalling pathways, which may restore immune function through activation of T cells and T-cell-mediated immune responses against tumour cells. PD-1 is a transmembrane protein in the immunoglobulin superfamily expressed on T cells that functions as an immune checkpoint negatively regulating T-cell activation and effector function when engaged by its ligands PD-L1 or PD-L2, and it plays an important role in tumour evasion from host immunity.
See it in motion
A schematic animation of the mechanism — simplified for clarity, not drawn to scale.
How penpulimab, an anti-PD-1 antibody, frees T cells against nasopharyngeal carcinoma
- Penpulimab is a monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1, PDCD1, CD279).
- Upon administration it targets, binds to, and inhibits PD-1 and its downstream signalling pathways, which may restore immune function through activation of T cells and T-cell-mediated immune responses against tumour cells.
- PD-1 is a transmembrane protein in the immunoglobulin superfamily expressed on T cells that functions as an immune checkpoint negatively regulating T-cell activation and effector function when engaged by its ligands PD-L1 or PD-L2, and it plays an important role in tumour evasion from host immunity.
- It is used for non-keratinizing nasopharyngeal carcinoma, with platinum chemotherapy and gemcitabine in the first-line setting and as a single agent after the disease has progressed through platinum-based chemotherapy and at least one other line of therapy.
Target: Programmed death-1 (PD-1) receptor
An immune checkpoint on T cells; when its ligands PD-L1 and PD-L2 activate it, T-cell activation and effector function are suppressed, which tumours exploit to escape immune attack.
Approved uses
Approved uses differ by country and change over time. Always follow your local prescribing information.
Approved uses in United States
FDA- In combination with either cisplatin or carboplatin and gemcitabine, for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma
- As a single agent, for the treatment of adults with metastatic non-keratinizing nasopharyngeal carcinoma with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy
Official sources
The statements on this page trace back to these records.
- DailyMed: penpulimab-kcqx official US label
U.S. National Library of Medicine, DailyMed
- U.S. Food and Drug Administration: penpulimab prescribing information
U.S. Food and Drug Administration
- National Cancer Institute: penpulimab
National Cancer Institute
This page explains how the medicine works — it isn’t the patient leaflet. For anything that applies to you, read the leaflet that came with your medicine or ask your pharmacist.
MedUnfold provides educational content and is not medical advice. Always follow your local prescribing information and healthcare professional.